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Organ transplantation in presensitized recipients 
continues to be contraindicated for heart and kidney 
recipients due to the risk of hyperacute rejection, 
which has no known treatment at this time. We tested 
whether donor serum, which contains solubie MHC 
class I antigen, is able to neutralize the effect of anti-
donor antibody in the recipient and prevent hyperacute 
or accelerated rejection. A rat model of passive immuni-
zation was used to test the role of anti-donor antibody 
in hyperacute rejection. Seven of 10 recipients of hy-
perimmune serum (HyS), derived from Lewis rats 
(ETI 1) following 3 ACI (RT1") skin grafts, developed 
hyperacute or accelerated rejection. intravenous injec* 
tion of ACI serum prior to the HyS administration pre-
vented hyperacute rejection in all recipients tested. 
When third-party (Wistar-Furth, RTl t t ) serum was 
given to Lewis rats injected with HyS, hyperacute re-
jection was not abrogated. When examining the mecha-
nism of this effect, a simple antibody blocking phenome-
non was found to be unlikely since flow cytometry anal-
ysis showed that ACI serum needed to be present at 
>256-fold excess compared to HyS to block anti-ACI 
antibody binding to RTl.A'-f- cells by 50%. We tested 
whether the RT1.A* class I antigen in ACI serum had 
other biologic properties that resulted in the prolonged 
graft survivah However, removal of RT1.A* antigen 
from ACI serum prior to use in the passive transfer 
model did not abrogate the graft Prolongation observed 
previously. These data suggest that components of do-
nor serum other than MHC class I antigen may be use-
ful for preventing the antibody-mediated component of 
hy per acute rejection. ® 199-1 Acndemie Frew, Inc. 
INTRODUCTION 
Renal transplantation in presensitized patients with 
preformed anti-donor antibody is contraindicated due to 
the risk of hyperacute or accelerated rejection. No 
current immunosuppressive modalities are effective in 
preventing antibody-mediated damage. If a cross-match 
test prior to human renal transplantation is positive, a 
different organ recipient must be selected. Currently 
40% of the patients awaiting renal transplantation are 
highly sensitized (>40% panel-reactive antibody) to Po-
tential donors, substantially reducing their chances of 
receiving a renal transplant. New Solutions to immuno-
therapy in sensitized patients are urgently needed. 
The purpose of this study was to determine whether 
solubie MHC class I antigen of the donor type has the 
abiiity to prevent or at least downregulate the immuno-
Jogic injury caused by anti-donor antibody. We therefore 
chose a rat model in which passive transfer of HyS at the 
time of cardiac allografting causes hyperacute rejection. 
Donor serum was used as a source of solubie class I anti-
gen. The reason for using a passive transfer model was to 
exclude the contribution of the primed cellular immune 
response. 
MATERIALS AND METHODS 
Animals 
Inbred male ACI rats (RT1°) were donors for skin and 
cardiac allografts. Male Lewis rats (RTl1) were recipi-
ents for all procedures, and Wistar-Furth (WF) rats 
(RTlu) were used as third-party controls. All rats 
weighed between 150 and 200 g and were obtained from 
Harlan Sprague-Dawley (Indianapolis, IN). 
HyS Preparation 
Two-centimeter-diameter ACI skin grafts were 
grafted onto the dorsal neck area of Lewis rats. After the 
first skin graft was rejected, the second and third ACI 
skin grafts were subsequently placed at 10- to 14-day 
intervals. HyS was collected 14-20 days after the third 
skin graft rejected. Sera from groups of sensitized Lewis 
rats were combined to make batches of pooled HyS. 
Batches of HyS were stored at -20°C for later use. 
Detection of Anti-RTl.Aa Antibody and RTl.A* Antigen 
Serum samples were diluted in phosphate-bufTered 
saline containing 0.5% bovine serum albumin. Fifty mi-
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FIG. 1. Flow cytometry histogram showing expression of RTl.A* 
in mouse L cells stably transfected with the cDNA for RTl.AV Non-
transfected L cells reacted with the same RTl.A*-specific antibody are 
shown. To demonstrate the expression of RTl.A*, cells were first 
reacted with R3/13 antibody (Bioproducts for Science, Indianapolis, 
IN) and then with goat anti-rat IgG-FITC. 
croliters of diluted serum was reacted with 5 X 106 
LRT7.5 cells in a 12 X 75-mm polystyrene tube for 30 
min at 4°C. LRT7.5 cells are a clone derived from mouse 
L-cells that were stably transfected with the cDNA en-
coding RTl.A* (cDNA provided by Dr. Jonathan How-
ard, Babraham Institute, Cambridge, UK); these cells 
constitutively express the RTl .A 8 molecule on their sur-
face (Fig. 1). After a 30-min incubation of the cell/serum 
mixture, cells were washed with diluent and resuspended 
to 100 fil Two microliters of goat anti-rat IgG-FITC 
(Jackson ImmunoResearch) was added to each tube and 
reacted for 30 min at 4°C. Cells were washed and ana-
lyzed by flow cytometry. 
In some experiments, sera were combined to deter-
mine whether solubie RTl.A* in ACI serum could neu-
tralize anti-RTl.A* antibodies in HyS. HyS and either 
ACI or normal Lewis (control) serum were mixed at 
various ratios, and incubated 1 hr at room temperature. 
After incubation, 50 /xl of each serum mixture was com-
bined with 5 X 105 LRT7.5 cells and left at 4°C for 30 
min. Cells were washed, reacted with goat anti-rat IgG-
FITC as described above, and analyzed by flow cytome-
try. The mean Channel of fluorescence (MCF) was de-
termined with the control reaction at each ratio of nor-
mal Lewis serum to HyS. The percent maximum MCF 
was calculated by dividing the MCF determined at a 
given ratio of ACI serum to HyS by the MCF determined 
at the same ratio of normal Lewis serum to HyS (control 
reaction). 
The level of RTl .A a antigen present in ACI serum was 
tested using a specific ELISA which has been described 
in detail previously [1]. Purified RTl.A* [1] was used as 
a Standard to determine the RTl.A" concentration. 
Depletion of RTl.A" from ACI Serum 
RTLA* was depleted from ACI serum using Sepha-
rose 4B (Sigma, St. Louis, MO) coupled to both OX-18 
(specific for monomorphic determinant of RTl.A; Bio-
products for Science, Indianapolis, IN) and RTl.A*-spe-
cific monoclonal antibody 211-4D9 (hybridoma pro-
vided by Heinz Kunz, University of Pittsburgh, Pitts-
burgh, PA). Serum was passed through the column 3X 
and was tested for RTl.A* before and after the depletion 
procedure. 
Cardiac Transplantation, Serum Transfer, and Histology 
Heterotopic abdominal cardiac allografting was per-
formed by the modified microvascular technique as de-
scribed previously [2]. Cardiac allografts were checked 
every 2 hr for the first 24 hr and then daily. The time of 
rejection was defined by palpation and direct visual in-
spection at laparotomy. Animals were bled via the tail 
vein to obtain serum for antibody testing. Serum was 
passively transferred intravenously following ACI heart 
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FIG. 2. (a) Measurement of anti-RTl.A* antibody titer in batches of HyS. Batches of HyS were diluted and tested for reactivity with the 
RTl.A*-expressing clone, LRT7.5. Antibody binding to LRT7.5 cells was detected with goat anti-rat IgG-FITC and was measured by determin-
ing the mean Channel of fluorescence (MCF) using flow cytometry. The titers of different batches of HyS are shown. (b) Measurement of 
anti-RTl.A - antibody titer after HyS serum injection into Lewis rats. Serum was obtained 1 hr after injection of HyS into two Lewis rat heart 
allograft recipients. The titers of anti-RTl.A» antibody in these sera are shown. 
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FIG. 3, (a) Effect of ACI serum injection on anti-RTl.A* antibody titer in an allograft recipient injected with HyS. The titer of anti-RTl.A* 
antibody in an allograft recipient was determined by flow cytometry 1 hr after injection of an allograft recipient with only HyS and 1 hr after 
another recipient was injected with ACI serum + the same HyS. Also, the anti-RTl.A" antibody titer was tested 1 hr after an additional 
recipient was injected with only ACI serum. (b) The in vitro effect of ACI serum addition on the araount of anti-RTl.A* antibody in HyS. ACI 
serum was combined with HyS at various ratios, and 5G>1 of each serum mixture was reacted with LRT7.5 cells to determine anti-RTl.A* 
antibody levels. The MCF at each ratio was compared to the maximum MCF, as determined by reacting normal Lewis serum with HyS at the 
same ratio. The % maximum MCF at each ratio of ACI to HyS is shown. 
transplantation. Animals in each of five groups were in-
jected with: (1) 2.0 ml HyS, (2) 2.5 ml ACI serum plus 2.0 
ml HyS, (3) 2.5 ml WF serum plus 2.0 ml HyS, (4) 2.5 ml 
ACI serum, or (5) no serum. 
Rejected hearts were formalin-fixed and embedded in 
paraffin. Six- to 8-Axm sections were cut and stained with 
hematoxylin and eosin. 
RESULTS 
Pooled HyS was tested for the presence of anti-
RTl.A* antibody. Flow cytometric analysis of HyS 
showed consistently high titers of anti-RTl.A* antibody 
in the different batches of HyS (Fig. 2a). Recipient 
serum obtained 1 hr after both heart transplantation 
and injection of 2.0 ml HyS, showed high levels of anti-
donor antibody (Fig. 2b). 
T A B L E 1 
Donor Serum Prevents Passive Transfer 
of Hyperacute Rejection 
ACI WF Graft survival time 
Group HyS serum serum (days) P value* 
1. _ _ 6, 6, 6, 6, 7 
2. - + - 4, 6, 6, 6, 6, 7 NS vs l 3. - - 0.2,0.2,0.9,1.1,2, 0.05 V8 1 2, 4, 8, 8, 8 
4. + - S, 9, 9, 9, 9, 9, 10, 0.004 vs 3 10 
5, + - + 0.6, 0.9, 2, 2,8,8,9 NS vs3 6. + b - 9,10, 10, 10, 10 NSvs4 
Note. NS, not significant (P > 0.10). 
a Mann-Whitney test. 
6 +ACI serum depleted of RTl.A" antigen. 
The effect of ACI serum injection on the titer of anti-
RTl.A* antibody in HyS-injected heart allograft recipi-
ents was determined. Transplanted rats injected with 
HyS serum, as well as ACI serum, did not show a de-
crease in anti-RTl.A* antibody levels compared to 
transplanted rats receiving only HyS (Fig. 3a). Serum 
collected at the same time point in transplanted rats 
injected with only ACI serum did not have detectable 
anti-RTl.A* antibody present. To test whether the solu-
bie RTl.A* in ACI serum is able to effectively reduce the 
titer of anti-RTl.A* antibody in HyS in vitro, ACI and 
HyS were mixed at various ratios, and the antibody titer 
was subsequently determined by flow cytometric analy-
sis (Fig. 3b). To reduce the MCF exhibited with HyS on 
LRT7.5 cells by 50%, ACI serum needed to be combined 
with HyS at a 256:1 ratio, respectively. Lower ratios of 
ACI to HyS serum reduced the MCF by <20%. To en-
sure the presence of RTl.A* antigen in ACI serum, an 
RTl.A*-specific ELISA was performed. Solubie RTl.A* 
was detectable at a concentration of 195 ± 92 (SD) ng/ 
ml in normal ACI serum (n - 5). 
Table 1 summarizes the survival times of heterotopic 
cardiac allografts in naive Lewis rats or rats injected 
with various combinations of sera. In the control group 
where no serum injections were performed, ACI hearts 
rejected at 6-7 days. Injection of 2.5 ml ACI serum alone 
had no effect on rejection time. Transplanted rats in-
jected with only HyS showed hyperacute or accelerated 
rejection in 7 of 10 recipients. Administration of ACI 
serum, prior to HyS, resulted in prolonged graft survival 
compared to HyS alone in all eight animals tested. To 
test the specificity of the effect of ACI serum, WF 
(third-party) serum was injected along with HyS after 
heart transplantation. The results show that four of 
seven grafts were rejected in a hyperacute or accelerated 
manner. Histologie evaluation of hearts rejected early 
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FIG. 4. (a) Cardiac allografts with hyperacute rejection developed severe edema, hemorrhage, infarction, and polymorphonuclear cell 
infiltration. (b) Hearts that rejected acutely (>6 days) showed massive lymphocyte inflltration and myocyte necrosis. 
(<4 days), regardless of treatment, showed features typi-
cal of humoral rejection with severe tissue edema, hemor-
rhage, infarction, and polymorphonuclear cell Infiltra-
tion (Fig. 4a). In contrast, hearts rejected at time points 
> 7 days showed histological evidence of severe lympho-
cytic inflltration, endothelialitis, and necrosis of myo-
cytes with replacement by flbroblasts (Fig. 4b). 
To determine whether solubie MHC class I antigen in 
donor-type serum has the ability to prevent or downre-
guiate the immunologic injury caused by anti-donor an-
tibody, ACI serum was depleted of RTl.A 8 antigen by 
affinity chromatography (Fig. 5) prior to injection with 
HyS. Data from these experiments show that the re-
moval of RTl.A* by this method did not abrogate the 
ability of ACI serum to prolong graft survival in the pas-
sive transfer model (Table 1). 
DISCUSSION 
Hyperacute rejection of transplanted organs is be-
lieved to be mediated primarily by donor-specific anti-
body present in the recipient at the time of transplanta-
tion. Donor-specific antibody binds to donor histocom-
patibility antigens, principally MHC class I antigen 
within the allograft, and initiates a complement-depen-
dent form of rapidly progressive tissue destrucüon 13-5]. 
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FIG. 5. Depletion of RTl.A* from ACI serum. ACI serum was 
depleted of RT1.A* by affinity chromatography and was subsequently 
tested for RT1.A" in an ELISA. Absorbance levels at the various 
serum dilutions are shown above. 
It has previously been demonstrated that hyperacute re-
jection of rat hepatic allografts can be readily produced 
in recipients presensitized by donor skin when the ap-
propriate inbred strain combinations are used [6]. The 
ACI to Lewis rat strain combination is a high-responder 
strain combination. In high-responder models, when 
three successive skin grafts are performed on the recipi-
ent, hyperacute rejection of skin, heart, and liver consis-
tently occurs both in an actively and a passively immu-
nized recipient (4, 7, 8], It has also been shown that im-
mediately following liver transplantation the liver 
releases significant amounts of solubie MHC class I mol-
ecules from the donor liver [9, 10], Infusion of solubie 
class I antigen derived from liver exträcts has been 
shown to prolong survival of subsequent cardiac allo-
grafts in a donor-specirlc manner in a nonsensitized 
model [11]. One explanation of the liver's relative resis-
tance to hyperacute rejection compared to other vascu-
larized organ allografts is that the donor-type MHC 
class I antigen blocks the destructive effects of anti-
donor antibody, either by neutralizing the antibody or 
through immunornodulatory effects of immune com-
plexes formed between the donor type MHC class I anti-
gen and donor-specific antibody [11-13]. However, a 
precise role of donor MHC class I antigen in conferring 
resistance to antibody-mediated rejection remains un-
clear. The goal of the current investigation was to isolate 
the effects of donor-type MHC class I antigen on anti-
body-mediated rejection of cardiac allografts using do-
nor serum as a source of MHC class I antigen. The con-
tribution of the sensitized cellular immune response was 
removed by passively transferring hyperimmune serum 
to an immunologically naive recipient. 
In the present study, hyperacute rejection was pre-
vented in a passive transfer model by injection of donor 
serum. The inhibition of hyperacute rejection by donor 
serum occurred despite the fact that the titer of anti-
donor antibody was unchanged in vivo with injection of 
ACI serum. Additionally, when HyS and ACI serum 
were combined in vitro, ACI serum needed to be added in 
large excess to reduce the anti-RTl.A* antibody titer 
substantially. Therefore, donor serum used in this man-
ner is not a feasible approach for lowering antibody 
titers, and our results cannot be explained by a simple 
antibody-blocking phenomenon. 
Donor serum was shown to contain substantial 
amounts of donor-type MHC class I antigen. The inabil-
ity of third-party serum to prevent hyperacute rejection 
suggested that the solubie antigens in the donor serum, 
principally MHC antigens, may have been responsible 
for this effect. These results are consistent with the hy-
pothesis that solubie donor MHC class I antigen can 
inactivate or downregulate antibody-mediated rejection. 
However, when RT1.A* class I antigen was depleted 
from ACI serum, the effect on antibody-mediated rejec-
tion in the passive transfer model was not abrogated. 
These results suggest that class I antigen is not the com-
ponent of donor serum preventing hyperacute rejection, 
or RTl.A" depletion from ACI serum was not complete. 
Incomplete depletion of RTl .A a is a possibility since the 
ELISA is only sensitive to 10 ng/ml. Another explana-
tion is that MHC antigens other than RT1.A (Lewis and 
ACI strains are a complete MHC mismatch) are in-
volved in this effect. 
The Prolongation of graft survival in recipients of hy-
perimmune serum who do not hyperacutely reject their 
cardiac allografts could be due to the weli-described phe-
nomenon of antiidiotypic antibody production which 
prevents acute rejection temporarily [14-16]. Why some 
recipients of HyS undergo hyperacute rejection while 
others have prolonged survival with passive enhance-
ment is unclear. The possibility of inducing hyperacute 
rejection by administering hyperimmune serum makes 
this strategy too risky as a means of preventing acute 
cellular rejection. 
The remarkable resistance of the liver to antibody-
mediated rejection [17, 18] may in part be due to its 
release of solubie MHC antigens following transplanta-
tion. Although our study suggests that serum MHC class 
I antigen alone plus anti-donor antibody is not solely 
responsible for preventing hyperacute or accelerated re-
jection in a passive transfer model, the mechanism of the 
donor-serum effect in this model Warrants further inves-
tigation using more concentrated sources of MHC anti-
gen. Further studies using recombinant MHC antigens 
are in progress to test its utility in preventing hypera-
cute or accelerated rejection in sensitized models of or-
gan transplantation. 
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